Physician profile
Tami K Sheldon
NPI 1164857504
$7,578.71
in general payments reported to CMS, 2019-2025
69 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what 98% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,330 · 2022: $1,713 · 2023: $1,469 · 2024: $1,582 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,323 · Long Term Medical Supply Or Device Loan: $1,196 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,323.46 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,826.03 | 2021-2025 | |
| Daiichi Sankyo INC. | $440.55 | 2021-2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $426.66 | 2021-2025 | Erleada, Darzalex, Balversa |
| Merck Sharp & Dohme LLC | $298.40 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $275.98 | 2021-2025 | Reblozyl, Augtyro |
| E.R. Squibb & Sons, L.L.C. | $235.80 | 2021-2025 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $235.20 | 2021-2025 | Tagrisso, Imfinzi, Enhertu |
| Genzyme Corporation | $226.38 | 2021-2024 | |
| Amgen INC. | $196.65 | 2021-2023 | Xgeva, Vectibix, Nplate |
| Pharmaessentia USA Corporation | $173.15 | 2023-2025 | Besremi |
| Kite Pharma, INC. | $156.54 | 2021-2025 | Yescarta |
| Exelixis INC. | $151.73 | 2021-2025 | Cabometyx |
| Abbvie INC. | $145.01 | 2022-2025 | |
| Pfizer INC. | $143.00 | 2021-2025 | |
| Taiho Oncology, INC. | $141.55 | 2021-2025 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tami Sheldon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.